What is the catalog number for Reparixin?

The catalog number for Reparixin is HY-15251.

What sizes are available for Reparixin?

Reparixin is available in the following size(s): 2 mg, 5 mg, 10 mg, 10 mM - 1 mL, 25 mg, 50 mg, 100 mg.

How many pack sizes does Reparixin come in?

Reparixin is available in 7 different pack sizes.

Is Reparixin in stock?

Reparixin is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures Reparixin?

Reparixin is manufactured by QuantiMol.

What is the estimated delivery time for Reparixin?

Estimated delivery time for Reparixin is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for Reparixin?

The safety data sheet for Reparixin is available here: http://file.medchemexpress.com/batch_PDF/HY-15251/Reparixin-SDS-MedChemExpress.pdf.

Reparixin

Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC50s of 1 and 100 nM, respectively.

Product Specifications

CAS Number

266359-83-5

Product Name Alternative

Repertaxin; DF 1681Y

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

CXCR

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology; Cancer

Assay Protocol

https://www.medchemexpress.com/Reparixin.html

Purity

99.99

Solubility

DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL

Smiles

CS(=O)(NC([C@@H](C1=CC=C(CC(C)C)C=C1)C)=O)=O

Molecular Formula

C14H21NO3S

Molecular Weight

283.39

Precautions

H302, H315, H319, H335

References & Citations

[1]Moriconi A, et al. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007 Aug 23;50 (17) :3984-4002.|[2]Bertini R, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2non-competitive allosteric inhibitor. Br J Pharmacol. 2012 Jan;165 (2) :436-54.|[3]Kim HY, et al. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. Biol Pharm Bull. 2011;34 (1) :120-7.|[4]Sousa LF, et al. Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice. Clinics (Sao Paulo) . 2013;68 (3) :391-4.|[5]Bertini R, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101 (32) :11791-6.|[6]Krishnamurthy A, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2016 Apr;75 (4) :721-9.|[7]Crespo J, et al. Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol. 2018 Jul 15;201 (2) :814-820.